Semaglutide, Wegovy & Ozempic in Vadodara: How GLP-1 Weight Loss Injections Work, Top Brands Compared, and What to Expect

If you have been researching weight loss options, you have almost certainly come across the names Wegovy, Ozempic, and semaglutide. These GLP-1 weight loss injections have become one of the most talked-about advances in obesity medicine worldwide — and increasingly, patients across Vadodara and Gujarat are asking their doctors about them. This guide breaks down exactly how semaglutide works, who it is suitable for, how the major brands compare, and what a doctor-supervised program looks like in practice.

What Is Semaglutide and How Does It Work?

Semaglutide belongs to a class of medications called GLP-1 receptor agonists. GLP-1, short for glucagon-like peptide-1, is a hormone your gut naturally produces after eating. Semaglutide is a lab-made version of this hormone that is roughly 94% similar to the natural one, but chemically modified so it stays active in the body for almost a full week instead of just minutes.

Once injected, semaglutide activates GLP-1 receptors in three key places: the pancreas, the gut, and the brain. In the pancreas, it prompts insulin release only when blood sugar is high, which is why it rarely causes low blood sugar on its own. In the gut, it slows down how quickly food empties from the stomach, which keeps you feeling fuller for longer. In the brain, it acts on appetite centers in the hypothalamus, directly reducing hunger signals and food cravings.

The combined effect is straightforward in practice, even though the biology is sophisticated: people simply eat less, feel satisfied sooner, and experience fewer cravings — which over weeks and months adds up to substantial, sustained weight loss.

Who Is a Good Candidate for Semaglutide Therapy?

Semaglutide therapy for weight management is generally suitable for adults who meet one of the following criteria:

• A BMI of 30 or higher (classified as obesity)
• A BMI of 27 or higher, combined with at least one weight-related health condition such as high blood pressure, type 2 diabetes, PCOS, or fatty liver disease
• A history of attempting diet and exercise-based weight loss without achieving lasting results

At SkinSio Clinics in Vadodara, every patient undergoes a detailed evaluation of BMI, weight history, and overall metabolic health before starting therapy. Patients with prediabetes or established type 2 diabetes alongside obesity often see particularly strong results, since semaglutide improves blood sugar control alongside weight loss.

There is also growing clinical interest in semaglutide for women with PCOS-related obesity, where central weight gain is often resistant to diet and exercise alone. Emerging data suggests a majority of obese PCOS patients who had not responded to lifestyle changes alone achieved significant weight loss once semaglutide was added to their treatment plan.

Semaglutide is intended to work alongside lifestyle changes, not as a replacement for them. The World Health Organization's current guidance on obesity management explicitly recommends combining GLP-1 therapy with structured dietary and physical activity support to achieve the best outcomes — which is why diet and exercise counselling is built into every semaglutide program at SkinSio Clinics.

Who Should Avoid Semaglutide? Contraindications & Precautions

Semaglutide is not appropriate for everyone. It is specifically contraindicated for individuals with:

• A personal or family history of medullary thyroid carcinoma (MTC), based on findings of thyroid C-cell tumours in animal studies
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Type 1 diabetes or diabetic ketoacidosis — semaglutide is not designed for this purpose
• Pregnancy, or plans to become pregnant within the next 2 months (semaglutide should be discontinued at least 2 months before attempting conception)
• Age under 12 years (Wegovy is approved from age 12 only for severe obesity, under specialist supervision)

Additional caution is needed for patients with a history of pancreatitis, gallbladder disease, diabetic retinopathy, or significant kidney impairment — these patients require closer monitoring throughout treatment.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation, particularly during the early dose-escalation phase. These effects are usually manageable by increasing the dose gradually and staying well hydrated, which is why supervised dosing schedules matter. Patients should also be aware of the boxed warning regarding thyroid tumours and should report any neck swelling, difficulty swallowing, or voice changes to their doctor immediately.

Top Weight-Loss Injection Brands Compared

Several FDA-approved GLP-1 and related injectable medications are currently used for weight management. Here is how the major options compare:

Of these, only Wegovy, Saxenda, and a small number of newer agents are specifically approved for weight management. Ozempic and Mounjaro are formally approved for type 2 diabetes, though their pronounced weight-loss effect has made off-label use for obesity extremely common worldwide.

Why Wegovy Stands Apart: The Novo Nordisk Advantage

Wegovy holds a unique position as the only semaglutide formulation approved solely for obesity management, rather than diabetes. This distinction matters clinically: Wegovy's approved dosing reaches a higher target dose of 2.4 mg weekly, compared to Ozempic's typical 1.0 mg, which translates into greater average weight loss in clinical trials.

Wegovy also made history as the first weight-loss medication to demonstrate a measurable cardiovascular benefit. A landmark trial found that Wegovy reduced major adverse cardiovascular events — including heart attack and stroke — by approximately 20% in people with obesity and existing cardiovascular disease. This cardiovascular protective effect is something other GLP-1 medications have not yet demonstrated at the same level, making Wegovy widely regarded by clinicians as the current gold-standard option specifically for obesity with cardiovascular risk.

The SkinSio Clinics Treatment Protocol

At SkinSio Clinics in Vadodara, semaglutide is offered as part of a structured, doctor-supervised medical weight management program — never as a standalone prescription without monitoring.

Step 1: Baseline Assessment

Before starting therapy, patients undergo baseline laboratory testing including blood glucose, lipid profile, thyroid function, and liver and kidney function tests. This ensures the patient is medically suitable and establishes a reference point to track progress safely.

Step 2: Gradual Dose Escalation

Treatment begins at a low starting dose, typically around 0.25 mg per week, increasing gradually every 4 weeks toward a maintenance dose — often in the range of 1.7 mg to 2.4 mg weekly, depending on individual response and tolerance. This slow escalation is the single most important factor in minimising gastrointestinal side effects. Patients are taught proper subcutaneous injection technique for the abdomen, thigh, or upper arm, rotating sites to prevent tissue irritation.

Step 3: Lifestyle Integration

Every patient is enrolled in a structured diet and activity plan alongside the injection schedule. SkinSio's dietitians and trainers work with patients to build a sustainable, moderate-calorie eating plan paired with regular physical activity — directly aligned with WHO recommendations that GLP-1 therapy works best when combined with comprehensive lifestyle support.

Step 4: Monitoring

Patients are monitored closely during the early weeks for gastrointestinal symptoms, with practical strategies such as eating smaller, more frequent meals and maintaining good hydration. Kidney function and electrolytes are periodically rechecked, since significant vomiting or diarrhoea can occasionally affect kidney function. Blood sugar is also tracked, particularly in patients who have diabetes alongside obesity.

Step 5: Follow-Up and Maintenance

Monthly follow-up visits track weight changes, review any side effects, and adjust the dose as needed. An important point patients should understand from the outset: stopping semaglutide abruptly after reaching a target weight often leads to partial weight regain. For this reason, most patients transition to a lower, ongoing maintenance dose after the initial 2–3 month intensive phase, rather than stopping treatment altogether.

Semaglutide Pricing in India and at SkinSio Clinics

GLP-1 therapy has become significantly more accessible in India in recent years. As of 2026, weekly costs across the market range widely: generic semaglutide vials can cost around ₹325 per week, branded Ozempic pens run approximately ₹1,415 per week, and Wegovy at its full 2.4 mg dose costs around ₹3,000 per week.

SkinSio Clinics offers a supervised weekly semaglutide program starting from ₹1,499 per week (approximately ₹6,000 per month), which includes both the medication and ongoing medical supervision — a combination that matters far more than price alone when it comes to safety and long-term success. The initial intensive phase typically runs for 2–3 months, after which patients are reassessed for a maintenance plan tailored to their results.

Pricing may vary based on dosing requirements and individual treatment plans. Call or WhatsApp +91 93220 22392 for current rates.

Combining Semaglutide with a Broader Wellness Plan

Weight loss often goes hand in hand with skin and body confidence goals. Many patients at SkinSio Clinics pair their semaglutide program with Non Surgical Fat Reduction for stubborn localised fat, or RF Skin Tightening to address loose skin as weight comes off. Our IV Infusions are also commonly used alongside semaglutide therapy to support hydration and energy levels during the adjustment period.

Is Semaglutide Right for You?

Semaglutide and related GLP-1 medications represent a genuine advance in obesity treatment — but they work best as part of a complete, medically guided program rather than a quick fix. The right candidate, the right starting dose, careful monitoring, and a realistic long-term plan are what separate a successful outcome from a disappointing one.

If you are considering semaglutide for weight loss in Vadodara, the most important first step is a proper consultation to assess whether you are a suitable candidate, review your health history, and discuss what realistic results look like for your specific situation.

Frequently Asked Questions